RESOLUTION OF THE EXPERT FORUM OF RUSSIAN FEDERATION "CHICKENPOX: SERIOUS INFECTION IN RUSSIAN FEDERATION, WHICH CAN BE PREVENTED DUE TO VACCINATION" DECEMBER 7, 2019

1. [Varicella and herpes zoster vaccines: WHO position paper, June 2014. (In English, French)]. Wkly Epidemiol Rec. 2014;89(25):265-287.

2. State report «О sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2017 godu”, dated 2018 June 1. Federal'naya sluzhba po nad-zoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka; 2018. (In Russ). Доступно по: https://rospotrebnadzor.ru/documents/details.php?ELEMENT_ID=10145. Ссылка активна на 12.07.2019.

3. State report «O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiyskoy Federatsii v 2018 godu”, dated 2019 June 3. Federal'naya sluzhba po nad-zoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka; 2019. (In Russ). Доступно по: https://rospotrebnadzor.ru/documents/details. php?ELEMENT_ID=12053. Ссылка активна на 12.07.2019.

4. Sanitary and epidemiological rules SP 3.1.3525-18 «Profilaktika vetryanoy ospy i opoyasy-vayushchego lishaya”, dated 2018 February 5. Federal'naya sluzhba po nad-zoru v sfere zashchity prav potrebiteley i blagopoluchiya cheloveka; 2018. (In Russ). Доступно по: https://minjust.consultant.ru/documents/39220. Ссылка активна на 12.07.2019.

5. Enders G, Miller E, Cradock-Watson J, et al. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet. 1994;343(8912):1548-1551. doi: 10.1016/s0140-6736(94)92943-2.

6. [National Advisory Committee on Immunization (NACI) update on varicella. (In English, French)]. Can Commun Dis Rep. 2004;30:1-26.

7. Gershon AA. Varicella zoster virus: prospects for control. Adv Pediatr Infect Dis. 1995;10:93-124.

8. Nathwani D, Maclean A, Conway S, Carrington D. Varicella infections in pregnancy and the newborn. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect. 1998;36 Suppl. 1: 59-71. doi: 10.1016/s0163-4453(98)80156-4.

9. Jura E, Chadwick EG, Josephs SH, et al. Varicella-zoster virus infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J. 1989;8(9):586-590. doi: 10.1097/00006454-198909000-00003.

10. Leung TF, Li CK, Hung E, et al. Immunogenicity of a two-dose regimen of varicella vaccine in children with cancers. Eur J Haemotol. 2004;72(5): 353-357. doi: 10.1111/j.1600-0609.2004.00216.x.

11. Hill G, Chauvenet A, Lovato J, McLean T. Recent steroid therapy increases severity of varicella infections in children with acute lymphoblastic leukaemia. Pediatrics. 2005;116(4):e525-529. doi: 10.1542/peds.2005-0219.

12. Giacchino R, Marcellini M, Timitilli A, et al. Varicella vaccine in children requiring renal or hepatic transplantation. Transplantation. 1995;60(9): 1055-1056.

13. Gershon A, Takakashi M, Seward J. Varicella vaccine. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Pennsylvania: W.B. Saunders; 2004. Рр. 784-823.

14. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4(1):26-33. doi: 10.1016/s1473-3099(03)00857-0.

15. Gnann JW, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347(5):340-346. doi: 10.1056/NEJMcp013211.

16. Centers for Disease Control and Prevention. Varicella. In: Atkinson W, Hamborsky J, McIntyre L, eds. Epidemiology and prevention of vaccine-preventable diseases. 10th ed. Washington DC: Public Health Foundation; 2007. Рр. 175-196.

17. Scott FT, Johnson RW, Leedham-Green M, et al. The burden of herpes zoster: a prospective population based study. Vaccine. 2006;24(9): 1308-1314. doi: 10.1016/j.vaccine.2005.09.026.

18. Schmader K, Gnann JW, Watson CP The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008; 197 Suppl 2:S207-215. doi: 10.1086/522152.

19. European Centre for Disease Prevention and Control (ECDC). Varicella Recommended vaccinations. Available from:

20. Bonanni P Gershon А, Gershonet M, et al. Primary versus secondary failure after varicella vaccination: implication for interval between 2 doses. Pediatr Infect Dis J. 2013;32(7):e305-e313. doi: 10.1097/ INF.0b013e31828b7def.

21. Prymula R, Bergsaker MR, Esposito S, et al. Protection against varicella with two doses of combined measles-mumps-rubella varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet. 2014;383(9925):1313-1324. doi: 10.1016/S0140-6736(12)61461-5.

22. Knuf M, Habermehl P Zepp F, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006;25(1):12-18. doi: 10.1097/01.inf.0000195626.35239.58.

23. Afonina NM, Mikheeva IV. Efficacy of vaccine prophylaxis of varicella using different tactics for its carrying out. Epidemiology and infectious diseases. 2019;(1):29-36. (In Russ). doi: 10.18565/epidem.2019.9.1.29-36.

24. Smirnova SS. Vetryanaya ospa — ugroza, kotoraya vsegda ryadom. (Conference proceedings) Ezhegodnaya vserossiyskaya nauchno-prakticheskaya konferentsiya s mezhdunarodnym uchastiyem spetsialistov po kontrolyu infektsiy, svyazannykh s okazaniyem meditsinskoy pomoshchi «Novyye tekhnologii v diagnostike, lechenii i profilaktike: ISMP, infektsii, parazitozy»; Tyumen', 2018 April 12-14. (In Russ).

25. Povey M, Henry O, Riise Bergsaker MA, et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infect Dis. 2019;19(3):287-297. doi: 10.1016/S1473-3099(18)30716-3.

26. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23(2):132-137. doi: 10.1097/01.inf.0000109287.97518.67.

27. Baxter R, Ray P Tran TN, et al. Long-term effectiveness of varicella vaccine: a 14-year prospective cohort study. Pediatrics. 2013;131(5): e1389-1396. doi: 10.1542/peds.2012-3303.

28. Halperin SA, Ferrera G, Scheifele D, et al. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age. Vaccine. 2009; 27(20): 2701-2706. doi: 10.1016/j.vaccine.2009.02.044.

29. Reisinger KS, et al. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and varivax. Pediatrics. 2006;117(2):265-272. doi: 10.1542/peds.2005-0092.

30. Yawn BP, Saddier P Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349. doi: 10.4065/82.11.1341.

31. Sengupta N, Booy R, Schmitt HJ, et al. Varicella vaccination in Europe: are we ready for a universal childhood programme? Eur J Pediatr. 2008;167(1):47-55. doi: 10.1007/s00431-007-0424-0.

32. Breuer J, Schmid DS. Varicella Oka variants and sequence variability in vaccine-related skin lesions. J Infect Dis. 2008;197 Suppl 2:S54-57. doi: 10.1086/522140.

33. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Preven tion. MMWR Recomm Rep. 1996;45(RR-11):1-36. doi: 10.1037/e547262006-001.